<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105921</url>
  </required_header>
  <id_info>
    <org_study_id>IRECAP</org_study_id>
    <nct_id>NCT03105921</nct_id>
  </id_info>
  <brief_title>Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma</brief_title>
  <official_title>Intérêt de l'électroporation irréversible Dans le Traitement de l'adénocarcinome du pancréas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the use of irreversible electroporation in the treatment
      of locally advanced cancers of the head of pancreas with vascular spread. This technique
      would allow to treat the unresectable part of the tumor to make it more accessible for a
      secondary surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the R0 resection (complete tumour removal with negative resection margins) rate of locally advanced pancreatic cancer treated by electroporation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Interventional Imaging</condition>
  <arm_group>
    <arm_group_label>Electrodes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NanoKnife</intervention_name>
    <description>The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.</description>
    <arm_group_label>Electrodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven adenocarcinoma of the head of the pancreas (fine
             needle aspiration or biopsy)

          -  Pancreatic adenocarcinoma locally advanced on imaging at diagnosis

          -  Tumor of less than 7 cm in largest diameter

          -  No chemotherapy or abdominal radiotherapy within five years before the inclusion in
             the study

        Exclusion Criteria:

          -  Pancreatic adenocarcinoma of more than 7 cm of diameter or immediately operable on
             imaging data

          -  Patient with contraindication of NanoKnife use

          -  Patient with neurostimulator

          -  Epileptic patient or with a myocardial infarction lasting less than 2 months

          -  Presence of visceral or lymph node metastases or peritoneal carcinosis at the initial
             workup

          -  Patient who cannot be treated with muscle blockers (curare)

          -  Patient with a metallic stent or a medical device implanted near the area treated by
             electroporation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Tougeron, MD, PhD</last_name>
    <phone>05 49 44 37 51</phone>
    <phone_ext>+33</phone_ext>
    <email>david.tougeron@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0549444665</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced pancreatic carcinoma</keyword>
  <keyword>Irreversible electroporation</keyword>
  <keyword>Interventional radiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

